The immune response in chronic hepatitis B virus infection: The “Core” of the problem? by Baker, James R. Jr.
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B VIRUS INFECTION: THE “CORE” OF 
THE PROBLEM? 
Ehata T, Omata M, Yokosuka 0, Hosoda K, Ohto M .  
Variations in Codons 84-101 in the Core Nucleotide 
Sequence Correlate with Hepatocellular Injury in 
Chronic Hepatitis B Virus Infection. J Clin Invest 
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ABSTRACT 
Individuals with chronic hepatitis B virus (HBV) 
infection are generally divided into asymptomatic 
healthy carriers and patients with chronic liver 
disease. Several studies have suggested that the hepa- 
titis B core antigen could be an immunological target 
of cytotoxic T lymphocytes (CTL). To investigate the 
possible pressure site from CTL, the entire core region 
of HBV DNA was sequenced in 30 subjects (10 asymp- 
tomatic healthy carriers and 20 patients with chronic 
liver disease). No significant changes in the nucleotide 
sequence and deduced amino acid residue were noted 
in the 10 healthy carriers. In contrast, a cluster of 
changes in a small segment of 18 amino acids (codons 
84-101 from the start of the core gene) was found in 15 
of the 20 chronic liver disease patients. All these 15 
patients had advanced liver diseases (chronic active 
hepatitis and cirrhosis), whereas only mild liver 
disease (chronic persistent hepatitis) was found in the 
five patients without mutations. These data suggest 
that the region with mutation clustering is the major 
target of CTL, and that the mutations evolve under the 
pressure of immune selection. 
COMMENTS 
Of the many patients infected with HBV, only approx- 
imately 10% progress to have chronic liver disease (1). 
Although the clinical and pathological stages in this 
progression are well documented, the mechanisms un- 
derlying the hepatocellular damage remain an enigma. 
These patients have evidence of chronic viral replication, 
as manifested by the presence of HBV DNA and HBeAg. 
However, the hepatic injury is not thought to be related 
to direct viral damage because HBV has not been 
demonstrated to be cytopathic. Instead, most attempts 
to explain the pathogenesis of the chronic liver disease 
have focused on host-related factors. 
The immune response to HBV infection is often 
implicated in the development of liver disease, and the 
hepatic injury is thought to result from the cellular 
immune response to infected hepatocytes (2). To under- 
stand the basis of this hypothesis, one must understand 
the mechanisms of immune recognition involved in 
cellular cytotoxicity. In response to viral infections, the 
immune system generates viral antigen-specific cyto- 
toxic T cells (3). The antigen receptor complex on these 
CD8 lymphocytes recognizes viral antigens as peptides 
bound to class I histocompatibility antigens on the 
surface of infected cells. The peptides are generated by 
digestion of viral antigens and can be as short as 12 to 
14 amino acids in length. Once the antigen receptors 
identify the peptide/class I complex, the T cells bind to 
the virus-infected cells. This binding is stabilized 
through the interaction of adhesion molecules. The T 
cells then lyse the virus-infected target cell (4). This 
action is essential in clearing a viral infection because of 
the need of destroying the intracellular source of viral 
replication. Released virus particles can then be neu- 
tralized and cleared by the circulating antibody. Thus 
hepatocytes are sacrificed by the immune system to 
control HBV. 
Several types of data support the central role that 
antiviral cytotoxic immune responses play in the normal 
immune clearance of HBV infection. Cellular immunity 
to HBcAg is seen in patients who clear the viral infection 
and become antigen negative (5). In contrast, the 
reactivation of viral replication is often seen in patients 
who are immunosuppressed or given immunosup- 
pressive medications (1). Evolution of chronic hepatitis 
B viremia to a nonreplicative, asymptomatic carrier 
state is often accompanied by the development of 
immunity to HBeAg (5 ) .  Importantly, whereas therapy 
with interferon may be effective in inhibiting HBV 
replication, it also augments antiviral cytotoxic immune 
responses in several ways (6).  This latter activity may be 
most important to interferon’s effectiveness in inducing 
viral clearance because agents that simply inhibit viral 
replication are rarely effective (7). 
If immunity is of benefit in resolving acute hepatitis B 
infection, how might it be deleterious in patients with 
chronic hepatitis B infection? A scenario can be envi- 
sioned where ongoing viral replication exists that for 
some reason cannot be controlled or eliminated. Cellular 
immune reactions continue to destroy infected cells; 
however, because the virus is not eliminated, this leads 
to progressive hepatic destruction. Such a scenario 
would require a paradoxical immune response: effective 
cytotoxic activity that can lyse infected hepatocytes, but 
the overall immune response that is, for some reason, 
unable to clear the infection. Although virulence char- 
acteristics of a particular strain of hepatitis B could be 
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implicated as causing an infection that cannot be 
cleared, they do not explain why only some patients with 
evidence of chronic viral replication do not have liver 
disease develop. Complicating this further, most chronic 
hepatitis patients do not have evidence of immune 
abnormalities (1). This indicates that no identifiable 
immune defect characterizes either patients with 
chronic liver disease or the asymptomatic carrier state. 
Thus the exact interaction between chronic hepatitis B 
infection and the immune system that leads to liver 
disease is not clear. 
In an attempt to clarify these issues, Ehata and his 
colleagues examined viral antigens from chronic hepa- 
titis B patients who had liver disease develop. They 
reasoned that chronic immune “pressure” from ongoing 
CD8 T-cell cytotoxicity might select mutations in the 
antigenic portions of the virus. Viral mutations devel- 
oping under pressure by immune surveillance have been 
reported in other viral infections, such as human 
immunodeficiency virus, where they give rise to virus 
variants that escape immune clearance (8). A similar 
event in hepatitis B might be related to the development 
of chronic infection. 
The authors compared 10 asymptomatic carriers with 
20 patients demonstrating liver disease who were all 
infected with the same subtype (adr) of hepatitis B. They 
examined the amino acid sequences of the antigens 
produced by HBV isolated from each of the patients and 
focused on the core antigen because it has been identified 
as a target of cellular immunity in patients with chronic 
infection. Using polymerase chain reaction, they were 
able to amplify out the coding sequence from the C gene 
of the virus and perform oligonucleotide sequence 
analysis. From this information, they deduced the amino 
acid sequence of the core antigen from each patient’s 
viral isolate. 
The result of this analysis was remarkable. Missense 
mutations were only present in the core antigens from 
patients with chronic liver disease. The core antigen 
amino acid sequences in the viruses isolated from the 
asymptomatic carriers were all identical with the con- 
sensus sequence reported for the adr virus subtype. In 
the patients with liver disease, however, very frequent 
amino acid substitutions were seen. Fifteen of the 20 
liver disease patients had amino acid substitutions in 
their core antigen. Importantly, an 18 amino acid 
fragment was seen that contained most of the substitu- 
tions in these patients. A single substitution, leucine for 
isoleucine at position 97, was found in 9 of 20 patients. 
The authors were also able to observe one patient 
serially and identified that the mutation in the gene 
coding for the core protein occurred after the devel- 
opment of cytotoxic immune damage (as evidenced by 
elevated serum ALT levels). This suggested that the 
mutations seen in these patients were de nouo and 
resulted from immune pressure on the virus. Finally, 
the mutations in the core protein were found to precede 
another described mutation in the hepatitis B genome, 
one that causes a stop codon in the precore gene 
preventing the production of the HBeAg. This seems to 
suggest that HBV, under pressure from the immune 
system, can continue to mutate until the virus is 
modified to prevent the production of antigenic parts of 
the molecule. 
These findings have immediate implications for the 
care of patients with chronic hepatitis B infection. 
Screening for mutations in the core antigen may provide 
a marker for patients destined to have liver disease 
develop. This would help guide therapy with interferon 
or antiviral drugs. The ability to predict the development 
of liver disease also might obviate the need for liver 
biopsy in some patients. For these reasons alone, the 
findmgs in this study are important. 
The more intriguing question is how these findings 
might help solve the riddle of why these patients have 
liver disease develop. These results fundamentally alter 
the concept of chronic hepatitis B infection. HBV can no 
longer be viewed as a passive entity in chronic infection. 
However, the exact role of the viral mutations these 
authors have observed is not obvious. The authors argue 
that the size of the area where most of the mutations 
occur is compatible with a T-cell epitope. This is possible, 
but this type of area in an antigen might also be 
compatible with an antibody epitope. In either case, if 
this area is a focus of immunological attack in the core 
antigen, it is possible that the mutations could lead to a 
virus that cannot be immunologically cleared. However, 
it is unlikely that this is the primary event in the 
induction of hepatocellular disease because evidence of 
liver damage precedes the development of the muta- 
tions. 
Another interpretation of this report is that the 
patients with liver disease have an abnormal immune 
response that causes hepatocellular damage and that 
this immune response also leads to core antigen muta- 
tions. Fortuitously, the results from this article may 
allow the examination of the immune response. With the 
localization of the immunogenic portions of the core 
antigen, synthetic peptides or recombinant fusion pro- 
teins can be produced that correspond to the amino acid 
sequences of the normal and mutated antigens. Cyto- 
toxic and proliferative T-cell responses to the normal 
and mutated core antigen may identify immune abnor- 
malities in patients who have liver disease. This could 
reveal the actual immune processes involved in what has 
become one of the most common causes of chronic liver 
failure. 
JAMES R. BAKER, JR., M.D. 
University of Michigan Medical School 
Ann Arbor, Michigan 481 03 
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AN “IRONIC” CASE OF MISTAKEN IDENTITY? 
Adams PC, Ghent CN, Grant DR, Frei JV, Wall WJ. 
Transplantation of a donor liver with haemochroma- 
tosis: evidence against an inherited intrahepatic defect. 
Gut 1991;32:1082-1083. 
ABSTRACT 
An iron loaded liver from a 40 year old man with 
occult haemochromatosis was transplanted into a 19 
year old woman with acute liver failure secondary to a 
paracetamol overdose. Increased parenchymal hepatic 
iron was found in a liver specimen at biopsy under- 
taken because of mild rejection 30 days after trans- 
plantation. After transplantation the patient had two 
episodes of liver rejection confirmed by biopsy. The 
hepatic iron concentration fell from 161 pmoVg on day 
30 after transplant to 26.6 pmol/g (normal < 40) on day 
210. Iron absorption, measured 46 days after trans- 
plant, was in the normal range at 12.4%. The rapid fall 
in hepatic iron and the normal iron absorption study 
result suggest that the genetic defect of haemochro- 
matosis is not exclusively an intrahepatic defect. 
COMMENTS 
General agreement exists that cirrhosis and HCC in 
hereditary hemochromatosis (HHC) are secondary to 
excess iron deposition in the liver. Until recently, 
however, controversy in the literature has existed 
regarding the mechanisms of iron overload in this 
disease. Some have argued that the underlying defect in 
body iron balance lies in the liver, whereas others have 
pointed to the gut as the source of the problem, offering 
evidence that increased absorption of iron by the 
duodenal mucosa is the cause of iron overload in HHC. 
Proponents of the hypothesis that iron overload in 
hemochromatosis is due to a hepatic defect have empha- 
sized the unique pattern of hepatic iron deposition in 
this disorder. Hepatic iron accumulation in HHC pa- 
tients is primarily parenchymal, with minimal depo- 
sition in reticular endothelial (RE) cells, at least in the 
early stages of the disease (1). As discussed recently by 
Bacon (21, this distinctive pattern of hepatic iron 
distribution has led to the controversial proposition that 
an intrinsic alteration of iron uptake, storage or 
transport by the RE cells in the liver of patients with 
HHC exists. An earlier study by Adams and coworkers 
(3) suggested that the level and pattern of hepatic iron 
deposition might influence iron absorption in rats. Six 
iron-overloaded livers from rats were transplanted into 
normal animals, and three normal livers were trans- 
planted into iron-loaded animals. Iron loading was 
achieved through oral and parented administration, 
and total body iron counting with SgFe was used to 
measure iron absorption. Oral iron loading with car- 
bony1 iron caused predominantly parenchymal iron 
deposition, whereas parented iron dextran adminis- 
tration resulted in RE cell iron deposition. Transplan- 
tation of livers with parenchymal iron overload into 
normal rats resulted in decreased iron absorption; 
however, transplantation of livers with RE cell iron 
overload had no effect on absorption as determined by 
this method. These results suggested not only that 
hepatic iron stores can influence iron absorption but also 
that the specific pattern of iron deposition within the 
liver can affect iron absorption. However, recent work in 
humans suggests that transferrin receptor expression in 
the hepatocyte plasma cell membrane is reduced in 
hemochromatosis patients just as in patients with 
secondary iron overload (4). Furthermore, hepatic trans- 
ferrin receptor is expressed inversely to the level of 
hepatic iron stores in patients with HHC (5) .  Pietrangelo 
et al. (6) subsequently have directly confirmed that 
hepatic transferrin receptor messenger RNA (mRNA) 
content is depressed in HHC (6). These studies demon- 
strated that transferrin receptor expression in the livers 
of HHC patients is appropriately decreased, arguing 
against the hypothesis that a primary disorder of hepatic 
transferrin-iron transport in HHC exists. 
A number of recent articles have examined iron 
absorption and transmucosal transfer in the proximal 
small intestine in patients with HHC. Immunohis- 
tochemical techniques have shown that duodenal mu- 
cosal content of ferritin in HHC patients is significantly 
lower than in controls or patients with secondary iron 
overload (7). At the molecular level, appropriate down- 
regulation of transferrin receptor mRNA in the duo- 
denum of patients with secondary iron overload is seen, 
which is accompanied by increased quantities of ferritin 
mRNA (8). In contrast, patients with HHC have high 
levels of transferrin receptor mRNA and low levels of 
mRNA for both ferritin H and L subunits. Kinetic 
studies of iron absorption in HHC patients using orally 
administered radiolabeled iron have been performed; 
analysis of rate constants for mucosal uptake and 
transmucosal transfer show no increase in mucosal 
uptake but rather accelerated transfer of iron from the 
mucosa to blood (9). The exact cause for this increased 
transfer of iron from the mucosa to blood in HHC 
patients is unknown, although it is tempting to spec- 
ulate that the failure of mucosal ferritin expression 
could remove the “gatekeeper” function of this iron 
storage protein. 
Two recent case reports serve nicely to illustrate the 
pathophysiological condition of iron metabolism in 
patients with HHC. In the article under discussion, 
Adams et al. report that a hemochromatotic liver was 
inadvertently transplanted into a patient with ful- 
minant liver failure caused by acetaminophen. A percu- 
